- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
BLS Pharmaceuticals Ltd (BLS)
BLS Pharmaceuticals Ltd stock price live, this page displays ASX BLS stock exchange data. View the BLS premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the BLS Pharmaceuticals Ltd real time stock price chart below.
What Is the BLS Pharmaceuticals Ltd Stock Price Today?
The BLS Pharmaceuticals Ltd stock price today is 0.935.
What Is the Stock Symbol for BLS Pharmaceuticals Ltd?
The stock symbol for BLS Pharmaceuticals Ltd is "BLS."
What Stock Exchange Does BLS Pharmaceuticals Ltd Trade On?
BLS Pharmaceuticals Ltd is listed and trades on the Sydney stock exchange.
Is BLS Pharmaceuticals Ltd a Good Stock to Buy?
Determining whether BLS Pharmaceuticals Ltd—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the BLS quote. (ISIN: AU0000477796)
What Is the BLS Pharmaceuticals Ltd Stock Price Today?
The BLS Pharmaceuticals Ltd stock price today is 0.935.
What Is the Stock Symbol for BLS Pharmaceuticals Ltd?
The stock symbol for BLS Pharmaceuticals Ltd is "BLS."
What Stock Exchange Does BLS Pharmaceuticals Ltd Trade On?
BLS Pharmaceuticals Ltd is listed and trades on the Sydney stock exchange.
Is BLS Pharmaceuticals Ltd a Good Stock to Buy?
Determining whether BLS Pharmaceuticals Ltd—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the BLS quote. (ISIN: AU0000477796)
Sydney
Currency in AUD
0.935
+0.015(+1.63%)
Closed·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.920
0.950
52 wk Range
0.350
1.295
BLS is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.9200.950
52 wk Range
0.3501.295
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
BLS Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
High return over the last year
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Technical Indicators
Strong Buy
Moving Averages
Neutral
BLS Pharmaceuticals Ltd Earnings Call Summary for Q2/2027
- BLS International posted record Q2 FY2027 revenue of INR 973 crore, up 32% YoY, though EBITDA margin fell to 25.5% from 28.9% prior year.
- Digital services surged 66% YoY while visa services grew 11%, creating margin pressure as lower-margin digital work now comprises larger revenue mix.
- Company targets FY2030 revenue of INR 6,300-6,500 crore with 20-25% annual growth and EBITDA margins of 28-30%; visa business to drive 60-65% of growth.
- Management expects net revenue per application to grow 5-6% annually from improved pricing; visa business to expand at least 15% yearly going forward.
- Firm holds net cash position of INR 1,665 crore for growth investments and selective acquisitions; stock fell 1.58% despite initial 4.33% pre-market gain.
Last Updated: 2026-11-04, 06:18 a/m
Read Full TranscriptEarnings
Latest Release
Oct 14, 2026
EPS / Forecast
-- / --
Revenue / Forecast
26.7M / --
Compare BLS to Peers and Sector
Metrics to compare | BLS | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipBLSPeersSector | |
|---|---|---|---|---|
P/E Ratio | 14.0x | −0.8x | −0.2x | |
PEG Ratio | 0.07 | 0.01 | 0.00 | |
Price/Book | 6.9x | 0.7x | 2.6x | |
Price / LTM Sales | 2.9x | 0.9x | 2.8x | |
Upside (Analyst Target) | - | 92.5% | 62.3% | |
Fair Value Upside | Unlock | 28.9% | 8.2% | Unlock |
BLS Pharmaceuticals Limited manufactures, imports, exports, and supplies controlled drugs and prescription medicines in Australia, the United Kingdom, Europe, and Japan. It operates through Manufacture/Sales Australia, Plant Based/UK/EU/JPN/AUS, and Wholesale PCC/USA segments. The Manufacture/Sales Australia segment engages in the manufacture and wholesale supply of preventive and novel medicines, cannabis, psilocybin, and MDMA under BLS. The Plant Based/UK/EU/JPN/AUS segment manufactures and distributes consumer health and novel food products under the Dr Watson brand. The Wholesale PCC/USA segment is involved in wholesale of patented Probiotics for gastrointestinal health and immunity. It also provides contract manufacturing services; and storage and distribution services. The company was formerly known as Bioxyne Limited and changed its name to BLS Pharmaceuticals Limited in June 2026. BLS Pharmaceuticals Limited is headquartered in Sydney, Australia.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the BLS Pharms (BLS) Stock Price Today?
The BLS Pharms stock price today is 0.935 AUD.
What Stock Exchange Does BLS Pharms Trade On?
BLS Pharms is listed and trades on the Sydney Stock Exchange.
What Is the Stock Symbol for BLS Pharms?
The stock symbol for BLS Pharms is "BLS."
What Is the BLS Pharms Market Cap?
As of today, BLS Pharms market cap is 211.880M AUD.
What Is BLS Pharms's Earnings Per Share (TTM)?
The BLS Pharms EPS (TTM) is 0.069.
From a Technical Analysis Perspective, Is BLS a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has BLS Pharms Stock Split?
BLS Pharms has split 3 times.
What is the current trading status of BLS Pharms (BLS)?
As of Nov 11, 2026, BLS Pharms (BLS) is trading at a price of 0.935 AUD, with a previous close of 0.935 AUD. The stock has fluctuated within a day range of 0.920 AUD to 0.950 AUD, while its 52-week range spans from 0.350 AUD to 1.295 AUD.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.